OxiGene gets patent for oncology product

By Elaine Rigoli

Tampa, Fla., May 5 - OxiGene, Inc. announced Friday that the U.S. Patent Office issued a patent for the company's lead clinical compound, Combretastatin A4P (CA4P).

The patent, entitled "Methods for Modulating Tumor Growth and Metastasis," U.S. Patent No. 7037906, provides broad coverage through 2021 for the use and administration of CA4P in combination with paclitaxel, one of the most widely used chemotherapeutic agents for oncology, the company said in a news release.

"This patent is of particular importance to OxiGene because we believe it substantially improves our market opportunity in oncology with the therapeutic combination of CA4P and paclitaxel. In our opinion, the patent has the potential to provide a distinct competitive advantage for the commercialization of CA4P in the oncology indications we are pursuing, including ovarian and lung cancers," president and chief executive officer Frederick Driscoll said in the release.

Data from early stage clinical trials combining CA4P with paclitaxel, or another chemotherapeutic agent, carboplatin, or both therapies combined, indicate antitumor activity and improved patient response, officials said.

OxiGene is an emerging pharmaceutical company developing small-molecule therapeutics to treat cancer and eye diseases and is based in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.